Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,263 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,110 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,003)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04929652 | Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer | unknown | Phase 1 / Phase 2 | 48 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT04926532 | Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma(Toripalimab) | unknown | Phase 1 / Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 15, 2021 |
| clinicaltrials |
| NCT04664504 | A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk | unknown | Phase 2 | 150 | Jing Jin, M.D.UNKNOWN | 1 | Jun 8, 2021 | clinicaltrials |
| NCT04913480 | SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 37 | The University of Hong KongOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04909866 | The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study | unknown | Phase 2 / Phase 3 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04907864 | Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE)(MIRACLE) | unknown | Phase 2 | 112 | Kil Yeon LeeOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT04814485 | Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer | unknown | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 25, 2021 | clinicaltrials |
| NCT04781686 | Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer | unknown | Phase 2 | 35 | Zhou FuxiangOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT04535024 | The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer | unknown | Phase 2 | 60 | Fudan UniversityOTHER | 1 | May 11, 2021 | clinicaltrials |
| NCT02942706 | Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC | unknown | Phase 2 / Phase 3 | 200 | Ruijin HospitalOTHER | 0 | Apr 30, 2021 | clinicaltrials |
| NCT03959150 | Metronomic Chemotherapy With Capecitabine for Pancreatic Cancer | unknown | Phase 2 / Phase 3 | 231 | Ruijin HospitalOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT04866381 | An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody | unknown | Phase 2 | 87 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 29, 2021 | clinicaltrials |
| NCT03620292 | Fluorescence Image Guided Surgery in Cholangiocarcinoma(COUGAR) | unknown | Phase 1 / Phase 2 | 12 | University Medical Center GroningenOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04814030 | Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial(AIPD-1) | unknown | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2021 | clinicaltrials |
| NCT02167321 | Rectal Cancer, Adjuvant Chemotherapy, FOLFOX(5-fluorouracil/Leucovorin/Oxaliplatin), Total Mesorectal Excision | unknown | Phase 2 | 90 | Yonsei UniversityOTHER | 1 | Apr 22, 2021 | clinicaltrials |
| NCT03971201 | A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion | unknown | Phase 2 | 200 | White Plains HospitalOTHER | 1 | Apr 14, 2021 | clinicaltrials |
| NCT04843943 | Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 0 | Apr 14, 2021 | clinicaltrials |
| NCT04442984 | FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)(IRIGA) | unknown | Phase 2 | 326 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT04838496 | Induction Chemotherapy for Locally Advanced Rectal Cancer(MEND-IT) | unknown | Phase 2 | 128 | Catharina Ziekenhuis EindhovenOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT04834986 | Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT02901301 | Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer | unknown | Phase 1 / Phase 2 | 41 | Yonsei UniversityOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT03585530 | Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus | unknown | Phase 2 | 32 | Huai'an First People's HospitalOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04833036 | c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI | unknown | Phase 2 | 120 | Fudan UniversityOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04826107 | Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer | unknown | Phase 2 | 196 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Apr 1, 2021 | clinicaltrials |
| NCT04826406 | A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs). | unknown | Phase 2 | 40 | Hunan Cancer HospitalOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04816045 | Neoadjuvant Electrochemotherapy for Colorectal Cancer - a Randomized Controlled Trial | unknown | Phase 1 / Phase 2 | 24 | Zealand University HospitalOTHER | 0 | Mar 25, 2021 | clinicaltrials |
| NCT04167293 | Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01)(ISBRT01) | unknown | Phase 2 / Phase 3 | 116 | Mian XIOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT04423965 | A Trial of Neoadjuvant mFOLFOXIRI Versus CRT in the EMVI Positive LARC | unknown | Phase 2 | 220 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT04563975 | Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer | unknown | Phase 2 | 54 | Tao ZhangOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04739046 | An Exploratory Trial to Evaluate Efficacy and Safety for Combination Treatment of Adenovirus Double Suicide Gene Therapy | unknown | Phase 2 | 12 | Seoul National University Bundang HospitalOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04801511 | Preoperative IMRT With Concurrent High-dose Vitamin C and mFOLFOX6 in Locally Advanced Rectal Cancer(CORT) | unknown | Phase 2 | 60 | Zhou FuxiangOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT03329664 | Autologous Killer Cell Therapy in Colon Cancer Patients | unknown | Phase 1 / Phase 2 | 20 | Sabz BiomedicalsINDUSTRY | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04797507 | SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer | unknown | Phase 2 | 33 | Peking Union Medical College HospitalOTHER | 0 | Mar 15, 2021 | clinicaltrials |
| NCT04797923 | A Phase II Study of Conversion Surgery After IP Paclitaxel With XELOX Chemotherapy in AGC With Peritoneal Dissemination | unknown | Phase 2 | 43 | Gangnam Severance HospitalOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04792515 | Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer(CCWSA/OAFLAG) | unknown | Phase 2 | 67 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT04777162 | Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer | unknown | Phase 2 | 40 | Peking UniversityOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT04781413 | Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer | unknown | Phase 1 / Phase 2 | 38 | Ruijin HospitalOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT04042805 | Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 36 | Baocai XingOTHER | 1 | Mar 2, 2021 | clinicaltrials |
| NCT04775862 | A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer. | unknown | Phase 2 | 60 | National Guard Health AffairsOTHER_GOV | 1 | Mar 1, 2021 | clinicaltrials |
| NCT03322969 | Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy | unknown | Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT04170179 | Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT04767295 | A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC) | unknown | Phase 2 | 28 | Hunan Cancer HospitalOTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT04749381 | The Role of TCM on ERAS of Rectal Cancer Patients(RCT) | unknown | Phase 2 | 264 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 11, 2021 | clinicaltrials |
| NCT03374293 | Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer | unknown | Phase 2 | 21 | Shixiu WuOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT04741165 | Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 72 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03941626 | Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies | unknown | Phase 1 / Phase 2 | 50 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04737213 | SGM-101 in Colorectal Lung Metastases(SGM-CLM) | unknown | Phase 2 | 10 | Leiden University Medical CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04508452 | A Phase II Prospective Trial of mXELOXIRI Reintroduction for mCRC | unknown | Phase 2 | 91 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT04733521 | A Phase 1/2 Study of SC-43 in Combination With Cisplatin | unknown | Phase 1 / Phase 2 | 100 | RaND BiosciencesINDUSTRY | 0 | Feb 2, 2021 | clinicaltrials |
| NCT04734249 | Second-line Surufatinib Combined With Chemotherapy in Advanced CRC | unknown | Phase 2 | 56 | Fujian Cancer HospitalOTHER_GOV | 0 | Feb 2, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Jun 18, 2021source: clinicaltrials